(Source: Astellas Pharma Inc) 037edda6-802a-4538-9bba-d2b86840b593.pdf Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan Tokyo and San Francisco, July 25, 2016 ─ Astellas Pharma Inc. (TSE:4503, "Astellas") and FibroGen, Inc. ("FibroGen"), today announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat (development code: ASP1517/FG-4592) for treatment of anemia in chronic kidney disease (CKD), which triggered a $10 million milestone payment from Astellas to FibroGen. The initiation of Phase 3 studies in Japan follows the positive...
↧